Peripheral inflammation is known to trigger neuroinflammation and neurodegenerative disease. However, the key components during the propagation of inflammation from the periphery to the central nervous system (CNS) remain unclear. Lipopolysaccharide (LPS) was administered to SpragueDawley rats to induce peripheral inflammation. An intravenous injection and an intranigral injection of clodronate liposomes were given to deplete monocytes and microglia, respectively. Recombinant CD200 fusion protein (CD200Fc) or an anti-CD200R1 antibody was injected into the substantia nigra to manipulate the involvement of CD200 and CD200R1. Immunohistochemistry and immunofluorescence staining were used to measure microglial activation and dopaminergic neuronal loss. The expression of brain pro-inflammatory cytokines (i.e., tumor necrosis factor alpha, IL-1b) and CD200-CD200R1 signaling were measured by quantitative RT-PCR. Our data showed that the peripheral LPS injection activated the microglia and induced an increase in the levels of pro-inflammatory cytokines (i.e., tumor necrosis factor alpha, IL-1b). The depletion of either monocytes or microglia suppressed these inflammatory effects that were induced by peripheral LPS administration. The peripheral LPS injection increased the expression of CD200 and CD200R1 in the substantia nigra. Dopaminergic neuronal loss induced by the peripheral LPS injection was accelerated by the blockade of CD200-CD200R1 signaling with an anti-CD200R1 antibody and attenuated by intensifying the signaling with CD200Fc. These results highlight the importance of monocytes, microglia, and CD200-CD200R1 signaling in the transmission of inflammation from the periphery to the CNS.
Neuroinflammation is one of the prominent pathological features of neurodegenerative diseases, including Parkinson's disease (PD). The characteristic features of neuroinflammation include the activation of glial cells and of a series of inflammatory mediators including pro-inflammatory cytokines, chemokines, reactive oxygen species, and nitric oxide (Hirsch and Hunot 2009; Heneka et al. 2015) . These elements are considered to be involved in the progression of neuronal degeneration (Pott Godoy et al. 2008) .
It is well established that peripheral inflammation can give rise to neuroinflammation and is linked closely to the etiology and progress of neurodegenerative diseases (Lim et al. 2015; Qin et al. 2016) . One famous study showed that a single intraperitoneal (i.p.) injection of lipopolysaccharide (LPS) resulted in the long lasting elevation of inflammatory cytokine levels and the delayed loss of dopaminergic neurons in the substantia nigra (SN) (Qin et al. 2007) . A recent study confirmed that gut microbiota was able to regulate motor symptoms and neuroinflammation in a model of PD (Sampson et al. 2016) . Moreover, concentrations of peripheral inflammatory cytokines such as tumor necrosis factor (TNF-a) and IL-1b were considered to be correlated with disease severity of PD patients (Qin et al. 2016) . These data strongly suggest the involvement of peripheral immunity dysfunction in the development of PD.
Microglia, as the surveillance cell of the CNS, plays a crucial role in regulating brain microenvironment (Yang et al. 2010) . Microglia is regarded as a first-line responder to some direct stimulation in the brain such as LPS treatment, proinflammatory cytokines and a-synuclein aggregation (Dheen et al. 2007) . Under pathologic conditions, microglia can transform from a quiescent phenotype into an amoeboid phagocytic phenotype and initiate the inflammatory response by producing cytokines, chemokines, nitric oxide, and reactive oxygen species (Yang et al. 2010; Luo and Chen 2012) and by cross-talking with other glial cells, blood-brain barrier (BBB) cells, and neurons (Tian et al. 2009; Fang et al. 2016) . Microglial activation is a hallmark of neurodegenerative diseases. Several researches demonstrate that microglia-mediated inflammatory response could contribute to increased neuronal injury (Du et al. 2016; Wolf et al. 2016) .
Monocytes are a key player in peripheral innate immunity. Recently, a growing body of research is focusing on the role monocytes play in neurological disorders. On the one hand, monocyte and microglia are considered to share the same origin of myeloid lineage as similar antigens, functions, and regulating mechanisms (Templeton et al. 2008) . Mounting evidence point out that monocytes could invade the CNS and be involved in the brain immune response in animal models of neurodegenerative diseases (Kim et al. 2016; Waschbisch et al. 2016) . On the other hand, monocytes in PD patients present impaired function and changed subpopulation (Drouin-Ouellet et al. 2015; da Silva et al. 2016) . These findings imply a close link between peripheral monocyte and neurodegenerative diseases.
CD200 is a surface glycoprotein that is mainly expressed by neurons, whereas its receptor (CD200R1) is mainly located in microglia in the CNS (Wang et al. 2007; Hernangomez et al. 2012) . Previous studies indicated that the activation of CD200R1 down-regulates the activity of myeloid cells such as microglia and macrophage (Hoek et al. 2000; Gorczynski et al. 2004) . It has been demonstrated that CD200-deficient mice exhibit increased microglial response and enhanced susceptibility to encephalomyelitis (Broderick et al. 2002) . On the other hand, the CD200R1 agonist, CD200 fusion protein (CD200Fc), alleviated age-related and LPS-induced activation of microglia (Cox et al. 2012) , ameliorated the inflammatory reactions associated with glial activation (Hernangomez et al. 2016) , and suppressed the development of neurodegenerative diseases (Liu et al. 2010; Zhang et al. 2011) .
Microglia, monocytes, and CD200-CD200R1 signaling are three elements which have been widely studied in models of endogenous neuroinflammation and neurodegenerative diseases. However, little is known about their roles in the regulation of neuroinflammation transmitted from the periphery. The way in which the peripheral immune system is connected with brain immunity and how peripheral inflammation is propagated to the CNS remains controversial. Here, we proposed that peripheral monocyte and brain microglia play key roles during the periphery-brain connection, and the reduction or abolition of either would interrupt the spread of inflammation from the periphery to the brain. Furthermore, we demonstrated that CD200-CD200R1 signaling is crucial in regulating peripheral inflammation-induced neuroinflammation and neurodegeneration.
Materials and methods

Animals
A total of 128 male Sprague-Dawley (8-week-old) rats weighing 200-250 g were used in the experiments. Rats were purchased from the Animal Center of China Medical University. All the experiments were in compliance with the National Institute of Health Guidelines (National Institutes of Health, Bethesda, MA, USA) and approved by the ethics committee of China Medical University. Animals were housed in groups (5 rats per cage) in a temperature-controlled environment with an ambient temperature of 22°C (AE 1°C) and a 12-h light-dark cycle. Food and water were provided ad libitum.
Before treatment, animals were numbered and acclimated for 1 week. Afterward, rats were randomly divided into the following groups according to a random number table ( Fig. 1): (1) a control group without treatment (Con group, n = 24); (2) a group treated with an i.p. injection of LPS (LPS group, n = 24); (3) a monocytedepleted group treated with an i.v. injection of clodronate liposome (CL) plus an i.p. injection of LPS [CL(i.v.)+LPS group, n = 10]; (4) a microglia-depleted group treated with an injection of CL into the right SN plus an i.p. injection of LPS [CL(SN)+LPS group, n = 10]; (5) a group treated with an injection of recombinant CD200Fc into the right SN (CD200Fc group, n = 10); (6) a group treated with an injection of CD200Fc into the right SN plus an i.p. injection of LPS (CD200Fc+LPS group, n = 10); (7) a group treated with an injection of anti-CD200R1 antibody into the right SN (anti-CD200R1 group, n = 10); (8) a group treated with an injection of anti-CD200R1 antibody into the right SN plus an i.p. injection of LPS (anti-200R1 + LPS group, n = 10); (9) a group treated with an injection of vehicle into the right SN (Veh group, n = 10); (10) a group treated with an injection of vehicle into the right SN plus an i.p. injection of LPS (Veh+LPS group, n = 10).
Peripheral stimuli LPS (strain O111:B4; Sigma-Aldrich, St Louis, MO, USA) was dissolved in phosphate-buffered saline (PBS, pH 7.4) at a concentration of 1 mg/mL. To generate peripheral inflammation, animals were given a single i.p. injection of LPS at 5 mg/kg.
Monocyte depletion
Clodronate liposomes (CL) were purchased from FormuMax Scientific (Sunnyvale, CA, USA). To generate monocyte-depleted rats, animals received an injection of CL into the lateral tail vein for 18 h (0.01 mL/10 g body weight). Phagocytosis of these liposomes initiated a clodronate-mediated suicide approach, which led to apoptosis in the monocytes/macrophages (van Rooijen et al. 1996; Sunderkotter et al. 2004) .
Stereotaxic surgery
For the stereotaxic injections, the animals were anesthetized with chloral hydrate (400 mg/kg) and placed in a stereotaxic apparatus.
The skull was exposed, and a dental drill was used to make a small hole to allow for the intranigral injection. The stereotaxic coordinates of the right SN were as follows: bregma + 4.8 mm; lateral + 1.8 mm; ventral À7.8 mm.
To deplete the microglia, rats received a 10-lL CL injection into the right SN 24 h before the peripheral LPS injection. To explore the role of the CD200-CD200R1 signaling, the rats were injected with CD200Fc Fig. 1 The treatment procedure of each group. A total of 128 male Sprague-Dawley (8-week-old) rats weighing 200-250 g were used in the experiments. Animals were numbered and acclimated for 1 week, then divided into the above groups according to a random number table. In step 1, we measured the effect of peripheral inflammation on neuroinflammation. Two groups were involved, including a control group without treatment and a lipopolysaccharide (LPS) group with a single i.p. injection of LPS at 5 mg/kg (n = 24 per group). The mRNA levels of tumor necrosis factor alpha (TNF-a),IL-1b,CD200,CD200R1 in the substantia nigra (SN) were measured at various time points after peripheral LPS injection (1 h, 3 h, 24 h, 7 days after; n = 4 per time point). Microglial activation and dopaminergic neuronal loss were measured at 14 days after peripheral LPS injection using immunohistochemical and immunofluorescence staining. In step 2, we measured the effect of monocyte/microglial depletion on peripheral LPS-induced neuroinflammation. Two groups were involved including a monocytedepleted group [clodronate liposome (CL)(i.v.)+LPS group] and a microglia-depleted group [CL(SN)+LPS group](n = 10 per group). Depletion of monocyte/microglia was performed at 24 h before peripheral LPS injection using intravenous/intranigral injection of CL. Before LPS injection, two rats were used to confirm the depleted effect in each group. In step 3, we measured the effect of CD200R1 agonist and antagonist on peripheral LPS-induced neuroinflammation. Six groups were involved including the Veh group, the Veh+LPS group, the CD200Fc group, the CD200Fc+LPS group, the anti-CD200R1 group and the anti-200R1 + LPS group (n = 10 per group). Intranigral injection of phosphate-buffered saline (PBS)/CD200Fc/anti-CD200R1 antibody was performed at 2 h before peripheral LPS injection. In Step 2 and Step 3, the expression of TNF-a and IL-1b in the SN were quantified at 24 h after peripheral LPS injection. Microglial activation and dopaminergic neuronal loss were measured at 14 days after peripheral LPS injection in all groups. i.p., intraperitoneal; CL, clodronate liposomes; SN, substantia nigra.
(5 lL, 2 lg/lL, Cat. No. 3355-CD; R & D Systems, Minneapolis, MN, USA) as an agonist of CD200R1 or with an anti-CD200R1 antibody as an antagonist of CD200R1 (5 lL, MCA1959; AbD Serotec, Oxford, UK) into the right SN 2 h before the peripheral LPS administration. A 10-lL Hamilton syringe was used for the intranigral injection. The injection was controlled at a rate of 1 lL/min and the syringe needle remained in position for 5 min to minimize reflux of the solution when the injection was finished.
Verification of monocyte depletion
The depletion of peripheral blood monocytes was determined using flow cytometry analyses of the blood specimens as described by Sunderkotter et al. (Sunderkotter et al. 2004) . Four rats were used for the experiment. Two rats were injected intravenously with CL for 18 h, and two rats not receiving treatment served as the control group. Blood specimens were collected in EDTA tubes (BD Vacutainer, Franklin Lakes, NJ, USA). Approximately 100 lL of blood was added to 2 mL of red blood cell lysing solution (Beyotime Institute of Biotechnology, Haimen, China) for 5 min, and samples were then centrifuged at 400 g at 22-26°C for 5 min. The supernatant was removed. The residual cells were washed twice with PBS and incubated with APC-conjugated anti-CD11b (BD Pharmingen, San Diego, California, USA) in 100 lL PBS containing 2% fetal bovine serum (FBS) at 4°C for 30 min on ice. Each measurement contained a defined number of 2 9 10 5 cells. Cell sorting was performed using a BD flow cytometer (LSRFortessa TM ; Becton Dickinson, Erembodegem, Belgium) and analyzed using FlowJo (flowjo.com).
Tissue preparation
At 24 h or 14 days post LPS injection, the rats were deeply anesthetized and perfused transcardially through the ascending aorta, first with saline and then with 4% paraformaldehyde dissolved in 0.01 M PBS (pH 7.4). The brains were dissected out, fixed in 4% paraformaldehyde in PBS (pH 7.4) for 24 h, and cryoprotected in a 30% sucrose solution in PBS at 4°C. The brains were frozen on a cold stage and sliced into 25-lm serial sections throughout the SN using a freezing microtome (CM1900; Leica Microsystems GmbH, Nussloch, Germany); then, the sections were stored in 65% glycerinum at À20°C for histological analysis.
Immunohistochemistry and immunofluorescence
Sections were pre-treated with 0.3% H 2 O 2 for 10 min to inhibit endogenous peroxidase activity, then rinsed in PBS three times. The sections were then blocked with diluted blocking serum for 1 h. Sections were labeled overnight at 4°C with the following primary antibodies: mouse anti-rat MHC-II (1 : 500; Abcam, Cambridge, UK), rabbit anti-rat CD200R1 (1 : 500; AbD Serotec), rabbit antirat tyrosine hydroxylase (TH) antibody (1 : 1000; Cell Signaling Technology, Beverly, MA, USA) and rabbit anti-rat Iba-1 (1 : 800; Wako Pure Chemicals Industries, Osaka, Japan). After the incubation, the sections were washed with PBS. For fluorescence analysis, sections were incubated with Alexa Fluor 488 or 594-conjugated secondary antibodies diluted at 1 : 1000 (Molecular Probes, Carlsbad, CA, USA) at 22-26°C for 2 h. Immunostaining sections were evaluated using a fluorescence microscope (Olympus BX51, Tokyo, Japan). For Immunohistochemistry staining, the sections were incubated with a biotinylated goat-anti-rabbit secondary antibody for 1 h after the incubation of primary antibodies, followed by an incubation with avidin-conjugated horseradish peroxidase for 1 h. 3,3'-diaminobenzidine (DAB) was used to develop the color. The sections were dehydrated using an alcohol gradient, cleared in xylene and cover slipped for microscopic analysis.
Quantitation of dopaminergic neurons
For quantitation of dopaminergic neuronal loss, TH-positive cells were counted through the whole SN using the optical fractionator technique with the aid of the Stereo-Investigator TM software (MBF Bioscience, Williston, VT, USA). Every sixth section throughout the entire SN of each rat was selected for analysis. For groups without intranigral injection [LPS group and CL(i.v.) +LPS group], results were expressed as percentage of the control group. For intranigral injected groups, the results were calculated as percentage of neurons on the injected hemisphere versus the intact contralateral hemisphere.
Quantitative RT-PCR (qRT-PCR)
RNA from the right side of the SN was extracted using Trizol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Total RNA was quantified photometrically and reverse transcribed using the PrimeScript TM RT Reagent Kit with the gDNA Eraser (Takara, Dalian, China). qRT-PCR was conducted using the SYBR Premix Ex Taq TM (Takara) and a Light Cycler 480 II RealTime PCR system (Roche Diagnostics, Basel, Switzerland). The relative expression between the groups was calculated using the 2 ÀDDCt method. The primer sequences were described in Table 1 .
Statistical analysis SPSS 17.0 software was used for statistical analysis. The data are expressed as the mean AE standard error of the mean (SEM). Student's unpaired t-test was used for comparisons between two means. For comparison of multiple range, we first measure the homogeneity of variance. When the homogeneity of variance was equal, one-way ANOVA followed by least significant difference (LSD) post hoc test was used. When the assumption of homogeneity of variances is not met, Welch's test was applied and Dunnett T3 test was used for comparison of pairwise significance. Statistical significance was set at p < 0.05. 
Results
Depletion of peripheral monocytes attenuated the neuroinflammation induced by peripheral LPS injection
Peripheral LPS induced pro-inflammatory cytokines change To characterize the effect of peripheral inflammation on the inflammation of the SN over time, TNF-a and IL-1b mRNA levels were quantified at 1 h, 3 h, 24 h, and 7 days. As shown in Fig. 2 , the i.p. administration of LPS induced a time-dependent increase in TNF-a and IL-1b expression in the SN. The TNF-a and IL-1b levels rapidly increased at 1 h and lasted at least 7 days after LPS exposure.
Intravenous CL injection eliminated monocytes
To test whether monocytes are crucial for peripheral LPSinduced neuroinflammation, we first depleted monocytes by i.v. injection of CL before the LPS challenge. The depletion of monocytes was confirmed by flow cytometry. After the i.v. injection of CL for 18 h, most monocytes in the blood disappeared (approximately 96%) (Fig. 3a) .
Depletion of monocytes attenuated the expression of proinflammatory cytokines induced by the peripheral LPS injection Then, 18 h after the i.v. injection of CL, the animals were i.p. injected with a single dose of LPS (5 mg/kg). We investigated the expression profiles of TNF-a and IL-1b in the SN of rats from each group at 24 h after the peripheral LPS injection. We chose 24 h as the time point because inflammation in the SN peaked at this time point, as shown in Fig. 1 . A significant decrease in the induction of TNF-a (p < 0.001) and IL-1b (p < 0.001) expression in the CL(i.v.)+LPS group was observed compared to the LPS group ( Fig. 3b and c) .
Depletion of monocytes suppressed the microglial activation induced by the peripheral LPS injection
We used immunohistochemical analysis of Iba-1 and MHC-II to determine the microglial response at 14 days after peripheral LPS injection. The LPS group showed clear microglial activation compared with the Con group and CL (i.v.)+LPS group ( Fig. 3d-f ). MHC-II-positive microglia could only be observed in the LPS group (Fig. 3h) . These results indicated that depletion of monocytes could suppress the neuroinflammation induced by the peripheral LPS injection.
The effect of monocyte depletion on dopaminergic neuronal survival We measured dopaminergic neuronal loss of the LPS group and the CL(i.v.)+LPS group at 14 days after peripheral LPS stimuli. The result showed that no significant difference in the numbers of dopaminergic neurons was observed between the CL(i.v.)+LPS group (95.2% of control) and the LPS group (93.7% of control). No dopaminergic neuronal cell death was observed in the LPS-treated group when compared to the control.
Depletion of microglia hindered the neuroinflammation induced by the peripheral LPS injection
Intranigral injection of CL eliminated microglia in the SN To evaluate whether the depletion of microglia can attenuate peripheral inflammation-induced neuroinflammation in the SN, we injected CL into the SN. After 24 h of CL injection to the SN, the number of Iba-1(+) microglia were significantly decreased in the CL-injected hemisphere compared to the non-injected hemisphere (approximately 73%), as shown in Fig. 4 (a) and (b).
Depletion of microglia attenuated the expression of proinflammatory cytokines induced by the peripheral LPS injection After 24 h of CL injection to the SN to remove the microglia, the rats received an i.p. injection of LPS for 24 h. A significant decrease in the mRNA expression of TNF-a (p < 0.001) and IL-1b (p < 0.001) was observed in the CL (SN)+LPS group compared to the Veh+LPS group ( 
Depletion of microglia does not protect dopaminergic neuron loss
We also measured the effect of microglial depletion on dopaminergic neuronal survival. Our results showed that both Veh+LPS group (70.0% of the contralateral side) and CL(SN)+LPS group (69.3% of the contralateral side) manifested a decrease in the number of dopaminergic neurons. However, there was no significant difference between these two groups. This result suggested that microglial depletion may not prevent dopaminergic neuronal loss induced by peripheral LPS injection.
CD200R1 activation attenuated the neuroinflammation induced by the peripheral LPS injection, and the CD200R1 blockade exacerbated the neuroinflammation
Peripheral LPS injection induced time-dependent alterations in CD200-CD200R1 expression in the SN Groups of animals were administered LPS at 1 h, 3 h, 24 h, and 7 days, and the expression of CD200 and CD200R1 mRNA was evaluated (Fig. 5) . Both CD200 and CD200R1 were quickly enhanced at 1 h after LPS stimuli. CD200 expression dropped to control levels at 24 h (Fig. 5a) . However, alterations in CD200R1 expression were timedependent, with a peak at 24 h and a decrease at 7 days when the expression was still higher than the control (Fig. 5b) . CD200R1-positive microglia could be observed at 24 h post LPS injection, while they could not be found in the control group (Fig. 5c-h ).
Intranigral injection of CD200Fc attenuated the expression of pro-inflammatory cytokines induced by the peripheral LPS injection, whereas the intranigral injection of anti-CD200R1 antibody increased the expression of pro-inflammatory cytokines To investigate whether CD200R1 activation can limit peripheral inflammation-induced neuroinflammation, we used an anti-CD200R1 antibody to block CD200-CD200R1 involvement and a CD200Fc that can activate CD200R1 to strengthen CD200-CD200R1 signaling. CD200Fc and anti-CD200R1 antibody were injected into the SN 2 h before the LPS administration and the expression of TNF-a and IL-1b were measured at 24 h post LPS injection. Pre-treatment with CD200Fc significantly decreased the expression of TNF-a and IL-1b compared with the Veh+LPS group (TNF-a: p = 0.021; IL-1b: p = 0.047) and the anti-CD200R1+LPS group (TNF-a: p < 0.001; IL-1b p = 0.048) (Fig. 6a and b) . In contrast, the anti-CD200R1+LPS group prominently enhanced the expression of TNF-a (p < 0.001) and IL-1b (p < 0.001) compared to the Veh+LPS group ( Fig. 6a and b) ; these data indicated that CD200R1 activation can attenuate the peripheral LPS injection-induced increase in pro-inflammatory cytokines in the SN and that the blockade of CD200R1 exacerbates this inflammation. Intranigral injection of CD200Fc attenuated microglial activation induced by the peripheral LPS injection, whereas the intranigral injection of the anti-CD200R1 antibody accelerated microglial activation We measured the microglial activation at 14 days after peripheral LPS injection (Fig. 6c-z) . The Veh+LPS group showed clear microglial activation in comparison with the CD200Fc+LPS group; this activation was higher in the anti-CD200R1+LPS group (Fig. 6) . The CD200FC+LPS group showed only a slight MHC-II immunoreactivity restricted to the needle tract (Fig. 6r) . In contrast, in the Veh+LPS group (Fig. 6p) , the MHC-II-positive microglia were centered around the injection track and covered more area. In the anti-CD200R1+LPS group (Fig. 6t) , the MHC-II-positive cells almost distribute the entire SN. Interestingly, we observed that the administration of anti-CD200R1 antibody could contribute to a chronic microglial activation similar to the Veh+LPS group and peripheral LPS injection aggravated anti-CD200R1 antibody-induced microglial activation. This result highlights the role of CD200R1 in maintaining microglia in a quiescent state, and blockage of this receptor drive microglia to be more sensitive to peripheral stimuli. The time-dependent mRNA levels of CD200, CD200R1 of the right substantia nigra after LPS injection. CD200 expression elevated at 1 h then rapidly decreased to a control level at 24 h (a). CD200R1 expression elevated at 1 h, peak at 24 h and decreased at 7 days when the expression was still higher than the control (
b). (c-h)
Immunofluorescent staining of Iba-1 (green) and CD200R1 (red) in the Con group (c-e) and the LPS group (f-h). CD200R1-positive microglia could be observed at 24 h post LPS injection, while could not be found in the control group. The bars represent the mean AE SEM (n = 3, each group, *p < 0.05 vs. control,**p < 0.01 vs. control). Scale bar, 50 lm.
Intranigral injection of CD200Fc suppressed the loss of dopaminergic neurons induced by the peripheral LPS injection, whereas the intranigral injection of the anti-CD200R1 antibody accelerated the loss of dopaminergic neurons We measured the dopaminergic neuronal loss at 14 days after peripheral LPS injection (Fig. 7a) . No dopaminergic neuronal loss could be observed in the Veh group (97.98% of the contralateral side, Fig. 7b ). The Veh+LPS group showed a significant decrease in the number of dopaminergic neurons (70.0% of the contralateral side; Fig. 7c ) compared with the Veh group. CD200Fc treatment significantly reduced the dopaminergic neuronal loss (91.5% of the contralateral side; Fig. 7q ) compared with the Veh+LPS group. Surprisingly, we observed that an intranigral injection of anti-CD200R1 antibody could contribute to neuronal injury at 14 days (77.3% of the contralateral side; Fig. 6r ), and no significant difference in the neuronal number was found between the was around the injection track and covered more area. CD200Fc treatment (f, l, r, and x) significantly suppressed the peripheral LPSinduced microglial activation compared with the Veh+LPS group (d, j, p, and v). The anti-CD200R1 group (g, m, s, and y) showed clear microglial activation similar to the Veh+LPS group. In the anti-CD200R1 + LPS group (h, n, t, and z), microglial activation was more significant and almost cover the entire SN. The bars represent the mean AE SEM (n = 4 each group. *p < 0.05, **p < 0.01). Scale bars, 500 lm in (c-h) and (o-t), 50 lm in (i-n) and (u-z).
anti-CD200R1 group and the Veh+LPS group. In the anti-CD200R1+LPS group (59.7% of the contralateral side; Fig. 6s ), the neuronal loss was more severe compared with the anti-CD200R1 group. These results highlight the crucial role of CD200-CD200R1 signaling in regulating the dopaminergic neuronal survival in the peripheral inflammation model.
Discussion
Monocytes are the decisive peripheral element in the process of neuroinflammation induced by peripheral inflammation A growing body of evidence demonstrates that peripheral inflammation can strongly influence the CNS (Ferrari and Tarelli 2011; Holmes 2013; Anthony and Couch 2014) .
Here, we used a single peripheral LPS injection to mimic systemic inflammation to research the relationship between the periphery and the brain. Our results demonstrated that the peripheral LPS injection could induce an inflammatory effect in the SN as demonstrated by the increase in proinflammatory cytokines and microglial activation. Interestingly, even though there was no significant dopaminergic neuronal loss in the LPS group compared with the control group at 14 days post LPS injection, which was in line with the result of Qin et al. (2007) , we did find significant neuronal loss when vehicle injection in brain was performed before LPS administration (see result 3.4). We speculated that a mechanical injury may increase the vulnerability of neurons stressed by neuroinflammation and precipitated the death of TH neurons as early as 14 days as in our case. In of Iba-1 (red) and TH (green) in each group. There was a significant loss of dopaminergic neurons around the injection track in the Veh+LPS group (o) and the anti-CD200R1 group (r). The neuronal loss is more evident in the anti-CD200R1 + LPS group (s). CD200Fc treatment (q) significantly reduced the neuronal loss induced by peripheral LPS stimuli (o). The bars represent the mean AE SEM (n = 5 each group, **p < 0.01,*p < 0.05). Scale bars, 500 lm.
line with our speculation, Villaran et al. (2010) confirmed that an injection of saline within the SN before peripheral inflammation induced by ulcerative colitis produced a 26.9% decrease in the number of TH-positive neurons at 10 days.
To clarify the role of monocyte during the propagation of inflammation from the periphery to the brain, we eliminated monocytes before the peripheral LPS injection by using i.v. administration of CL, which is known to trigger the apoptosis of monocytes/macrophages (Van Rooijen and Sanders 1994) . Our results showed that the depletion of monocytes could suppress the peripheral LPS-induced increases of proinflammatory cytokines and microglial activation in the SN.
In this way, we demonstrated that monocyte is a key peripheral factor in the periphery-brain propagation of inflammatory signals, and the elimination of monocytes blocked the transmission of inflammation from the periphery to the CNS. Possible ways monocytes participate in the periphery-brain communication include the direct differentiation of brain cells such as microglia (Stalder et al. 2005; Simard et al. 2006) , perivascular cells (Priller et al. 2001; Prodeus et al. 2014) , meninges and choroid plexus cells (Kim et al. 2005) , along with their indirect interactions with lymphocytes (Waschbisch et al. 2016) , or BBB cells (Man et al. 2012) to affect their immunological activities in the CNS.
To investigate the role of monocyte in peripheral inflammation-induced neurodegeneration, we measured the THpositive cells in the Con group, the LPS group, and the CL (i.v.)+LPS group. Our results showed that there was no significant difference regarding the TH-positive cells among the three groups. Indeed, Qin et al. (2007) pointed out a significant loss of DA neurons beginning at 7-month postperipheral LPS treatment, and the loss was closely related to persistent inflammatory stimulus. Our results were not able to demonstrate the effect of monocyte depletion on neuronal survival because of the short term of observation. However, we observed that monocyte depletion could block the neuroinflammation induced by systemic inflammation. Thus, we speculate this treatment might prevent dopaminergic neuronal loss. This should be further evaluated for a longer time course. Considering the crucial role of monocytes in regulating peripheral immunity and the transmission of inflammatory signals from the periphery to the brain, we speculated that the manipulation of monocyte function may be used as a therapeutic target to delay the development of neurodegenerative diseases. Consistent with this notion, Villaran et al. (2010) confirmed that ulcerative colitis reinforced the inflammatory and deleterious effects of an intranigral LPS injection, whereas the depletion of circulating monocytes suppressed this effect.
Microglia represent the decisive central element in the propagation of inflammation from the periphery to the brain In this study, we confirmed that a peripheral LPS injection significantly increased the production of pro-inflammatory cytokines in the SN, whereas the elimination of resident microglia by CL before the peripheral LPS administration was able to block the elevation of TNF-a and IL-1b levels in the SN. These results implied that microglia mediated most of the sources of cytokine production within the substantia nigra and is also essential brain component in the propagation of inflammation from the periphery to the brain. The depletion of microglia would contribute to the direct blockage of microglia-derived cytokine production, and the cell-cell communication between the microglia and the BBB cells could also be blocked, further reducing the cytokine production from BBB cells and protecting the integrity of the BBB (Lecuyer et al. 2016) . This indirect route could also affect the infiltration of the peripheral immune cells, as some studies demonstrated that BBB disruption is a crucial condition for leukocyte migration (Ajami et al. 2007; Mildner et al. 2007 ).
CD200-CD200R1 signaling is the major type of signaling in the peripheral inflammation model Several studies confirmed the importance of CD200-CD200R1 signaling as a crucial down-regulator of endogenous CNS inflammation (Liu et al. 2010; Zhang et al. 2011) . However, whether the CD200-200R1 pathway also plays a key role in the regulation of neuroinflammation transmitted from the periphery has not been investigated. In this study, we first measured the expression of CD200 and CD200R1 in the SN after peripheral LPS injection. Our results showed that peripheral LPS significantly up-regulated the mRNA level of CD200 at 1 h and rapidly decreased to a control level at 24 h. Similar results have been confirmed by Masocha (2009) . His study described an up-regulation of CD200 expression in the whole brain at 4 h after peripheral LPS injection. The elevation of CD200 expression might be caused by peripheral LPS-induced neuroinflammatory response. It has been verified that anti-inflammatory cytokines such as IL-4 and IL-10 enhance the CD200 expression on neurons (Lyons et al. 2007; Hernangomez et al. 2012) . However, contrary to our results regarding microglial CD200R1 expression, Masocha also demonstrated that peripheral LPS could reduce brain CD200R expression. We guess that this is because we measured a different part of brain. Microglia within different brain regions differ in morphology (Harry and Kraft 2012) , density (Sharaf et al. 2013) , distribution and function (Olah et al. 2011; Sharaf et al. 2013) . Different microenvironments in particular brain regions were considered to influence the functional change and receptor expression of microglia (Olah et al. 2011) . Thus, the heterogeneity may contribute to region-specific different susceptibility to inflammation (Kim et al. 2000; Anthony and Couch 2014) and difference of CD200R expression. On the other hand, the fact that we used different animals may provide another explanation; we used SpragueDawley rat, whereas they used C57BL/6 mice.
To investigate the regulatory role of CD200R1, we stimulated CD200R1 using an agonist (CD200Fc) and blocked CD200R1 using an antagonist (anti-CD200R1 antibody) before the peripheral LPS injection. CD200Fc treatment has been shown to inhibit key microglial functions such as antigen presenting capacities and secretion of proinflammatory cytokines in a murine model of multiple sclerosis (Liu et al. 2010) . In accordance with these results, we observed that pre-treatment with CD200Fc led to a significant suppression of peripheral LPS-induced microglial activation and the expression of inflammatory cytokines in the SN, whereas pre-treatment with anti-CD200R1 antibody aggravated these inflammatory responses. These results suggest that CD200-CD200R1 signaling is a crucial downregulator of peripheral LPS-induced neuroinflammation. In addition, CD200Fc has been shown to increase the expression of anti-inflammatory cytokines such as IL-4 and IL-10 ( Lyons et al. 2007; Hernangomez et al. 2012 ) and disturb TLR4-dependent pathways in microglia (Jiang et al. 2016) .
Many studies have demonstrated a link between CD200-CD200R signaling deficiency and neurodegenerative diseases. For instance, Walker et al. (2009) described a reduced expression of CD200 and CD200R in the hippocampus and inferior temporal gyrus of patients with Alzheimer's disease. Here, we measured the role of CD200R1 agonist and antagonist in peripheral inflammation induced neurodegeneration. Our results documented that attenuation of microglial activation by CD200Fc could protect dopaminergic neurons from neuroinflammation induced by peripheral inflammation, whereas potentiation of microglial activation by anti-CD200R1 antibody injection could be detrimental to neurons. These results highlight the neuroprotective role of CD200Fc in peripheral inflammation. Similar to our study, in animal models of neuropathic pain (Hernangomez et al. 2016) and multiple sclerosis (Liu et al. 2010) , CD200Fc treatment has been confirmed to suppress the disease progression. In contrast, injection of a CD200R-blocking antibody into striatum could accelerate the development of Parkinson's disease in animal research (Zhang et al. 2011) .
In this study, we also evaluated the effect of microglial depletion on neuronal survival and our results suggested that either microglial depletion or CD200Fc treatment could suppress the expression of pro-inflammatory factors. However, only CD200Fc manifested a neuroprotective effect by preventing dopaminergic neuronal loss. There are several explanations for the difference in neuroprotective effect. Microglia have dual roles in the maintenance of the neural environment (Le et al. 2016) . It could both provide benefits and cause harm to neurons depending on the specific situation. When treated with CD200Fc, only the microglial activation was inhibited and physiological function was preserved; thus, neurotoxicity can be suppressed, whereas neuroprotective effects remained as demonstrated in Hernangomez et al. (2016) . However depletion of microglia may diminish not only the possible neurotoxic effect but also the beneficial function including releasing neurotrophic and anti-inflammatory factors (Ding et al. 2004) , as well as clearing toxic substance (Gao and Hong 2008) . In addition, microglial depletion may be too severe, and that could have a robust impact on other cells (Asai et al. 2015; Torres et al. 2016) . Some research reported a significant astrocytic change after microglial depletion in vivo (Asai et al. 2015; Torres et al. 2016 ). Moreover, it is possible that treatment with CL does not ablate total microglial activity, and it might even worsen neuronal injury.
Taken together, our study provides evidence that microglia play a crucial role in regulating dopaminergic neuronal survival, and CD200Fc may serve as a potential therapeutic approach for neuroprotection in chronic inflammatory states in the CNS. However, our study is limited in that we did not measure the effect of Fc protein on CNS immune response. We cannot exclude the possibility that other systems may be involved in the procedure. Thus, further study is needed to clarify the mechanism involved in the peripheral LPSinduced microglial activation and neuronal degeneration.
Conclusion
Our study demonstrated that peripheral monocytes and their corresponding CNS microglia play key roles in the propagation of inflammation from the periphery to the brain, and that, without either, there would be no transmission of inflammation from the periphery to the CNS. In addition, CD200-CD200R1 signaling is critical in regulating neuroinflammation induced by peripheral inflammation. Manipulating any of the critical components in the pathway of inflammation transmission from the periphery to the brain will exert a significant neuroprotective effect and might provide some insight into the strategy of treating neurodegenerative diseases while the pathological process is underway.
